Imbioray (Hangzhou) Biomedicine Co., Ltd.

Primary Objective: To evaluate the preliminary efficacy of IBR854 cell injection combined with pemetrexed + cisplatin versus pemetrexed + cisplatin in patients with locally advanced or metastatic non-squamous non-small cell lung cancer. Secondary Objectives: 1) To evaluate the safety of IBR854 cell injection combined with pemetrexed + cisplatin versus pemetrexed + cisplatin in patients with locally advanced or metastatic non-squamous non-small cell lung cancer. 2) To evaluate the pharmacokinetic characteristics of IBR854 cell injection combined with pemetrexed + cisplatin after administration. 3) To evaluate the immunogenicity of IBR854 cell injection. Exploratory Objectives: 1) To evaluate the cytokine release profile and its correlation with clinical efficacy and safety. 2) To explore the correlation between 5T4 expression levels and clinical efficacy.